Nausea News and Research RSS Feed - Nausea News and Research

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
Imatinib-related symptom burden linked to adherence in Indian CML patients

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. [More]
AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Weekend effect in hospitals affect kidney stone treatment, outcomes

Weekend effect in hospitals affect kidney stone treatment, outcomes

Patients with severe cases of kidney stones are 26 percent less likely to receive timely treatment when they're admitted to the hospital on the weekend, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine. [More]
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than patients who received radiation therapy alone, according to the results of the clinical trial, Radiation Therapy Oncology Group 9802 published in the April 7 issue of the New England Journal of Medicine. [More]
Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Thirteen-year-old Madeline Yunker fell hard during a soccer match three years ago, striking her head on the turf with enough force to cause a concussion. [More]
FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). [More]
Four commonly used medications to treat pregnant women with migraines may not be safe

Four commonly used medications to treat pregnant women with migraines may not be safe

According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be. [More]
NHS England to provide crucial funding for Janssen's HIV treatment, REZOLSTA

NHS England to provide crucial funding for Janssen's HIV treatment, REZOLSTA

Janssen-Cilag Ltd today announced that NHS England will provide crucial funding for its once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called REZOLSTA. [More]
Concussion-related symptoms improve following initial session of OMT

Concussion-related symptoms improve following initial session of OMT

Two case reports published in The Journal of the American Osteopathic Association document improvements in concussion-related symptoms following an initial session of osteopathic manipulative treatment (OMT). [More]
UCI researchers get $8 million to help develop new vaccine for Q fever

UCI researchers get $8 million to help develop new vaccine for Q fever

A University of California, Irvine scientific team led by infectious diseases researchers Philip Felgner and Aaron Esser-Kahn has received $8 million from the U.S. Department of Defense's Defense Threat Reduction Agency to help develop a new vaccine for Q fever. [More]
Yellow fever outbreak in Angola kills 178 people

Yellow fever outbreak in Angola kills 178 people

Angola is grappling with a yellow fever outbreak, which has infected more than 450 people and killed 178 – the first epidemic of the disease to hit the country in 30 years. [More]
Anticonvulsant medication gabapentin effectively reduces common complication of PONV

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

The anticonvulsant medication gabapentin—already a useful part of strategies to control pain after surgery—also effectively reduces the common complication of postoperative nausea and vomiting (PONV), reports a study in Anesthesia & Analgesia. [More]
Advanced genomic sequencing tracks deadly blood infection in cancer patients

Advanced genomic sequencing tracks deadly blood infection in cancer patients

The Translational Genomics Research Institute, working with international investigators, have discovered the source of a potential deadly blood infection in more than 50 South American cancer patients. [More]
Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. [More]
MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

MUSC surgeon awarded $3.8 million grant to evaluate transplant drug

Seldom can one say $3.8 million is just the tip of the iceberg, but a newly awarded grant from Gilead Sciences, Inc. is just that. MUSC transplant surgeon Kenneth Chavin, M.D., Ph.D., says the true value of the multi-center drug trial is closer to $26 million, including $22 million in free drugs provided by the pharmaceutical company. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. [More]
Advertisement